rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
9
|
pubmed:dateCreated |
2005-9-13
|
pubmed:abstractText |
The value of PET or PET/CT with (18)F-FDG for the staging of penile cancer has yet to be determined. The objective of this study was to investigate the pattern of (18)F-FDG uptake in the primary malignancy and its metastases and to determine the diagnostic value of (18)F-FDG PET/CT in the staging and restaging of penile cancer.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0161-5505
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1460-5
|
pubmed:meshHeading |
pubmed-meshheading:16157528-Adult,
pubmed-meshheading:16157528-Aged,
pubmed-meshheading:16157528-Aged, 80 and over,
pubmed-meshheading:16157528-Carcinoma,
pubmed-meshheading:16157528-Fluorodeoxyglucose F18,
pubmed-meshheading:16157528-Humans,
pubmed-meshheading:16157528-Lymphatic Metastasis,
pubmed-meshheading:16157528-Male,
pubmed-meshheading:16157528-Middle Aged,
pubmed-meshheading:16157528-Neoplasm Staging,
pubmed-meshheading:16157528-Penile Neoplasms,
pubmed-meshheading:16157528-Positron-Emission Tomography,
pubmed-meshheading:16157528-Prognosis,
pubmed-meshheading:16157528-Radiopharmaceuticals,
pubmed-meshheading:16157528-Reproducibility of Results,
pubmed-meshheading:16157528-Risk Assessment,
pubmed-meshheading:16157528-Risk Factors,
pubmed-meshheading:16157528-Sensitivity and Specificity,
pubmed-meshheading:16157528-Severity of Illness Index,
pubmed-meshheading:16157528-Subtraction Technique,
pubmed-meshheading:16157528-Tomography, X-Ray Computed
|
pubmed:year |
2005
|
pubmed:articleTitle |
18F-FDG PET/CT for staging of penile cancer.
|
pubmed:affiliation |
Department of Nuclear Medicine, University of Munich, Munich, Germany. Bernhard.Scher@med.uni-muenchen.de
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|